Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December

Merus (NASDAQ:MRUS - Get Free Report) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 8,260,000 shares, a decline of 15.5% from the December 15th total of 9,780,000 shares. Based on an average trading volume of 539,100 shares, the short-interest ratio is presently 15.3 days.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MRUS shares. Needham & Company LLC restated a "buy" rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 9th. HC Wainwright restated a "buy" rating and set a $85.00 target price on shares of Merus in a report on Monday, December 2nd. UBS Group started coverage on Merus in a report on Thursday, October 24th. They issued a "buy" rating and a $72.00 price target for the company. Guggenheim reissued a "buy" rating and set a $109.00 price objective (down previously from $111.00) on shares of Merus in a report on Tuesday, December 3rd. Finally, Citigroup boosted their target price on shares of Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $85.64.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Merus by 17.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company's stock worth $4,207,000 after purchasing an additional 12,212 shares during the period. GSA Capital Partners LLP acquired a new stake in Merus during the 3rd quarter worth $675,000. Driehaus Capital Management LLC raised its stake in Merus by 26.4% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,550,009 shares of the biotechnology company's stock worth $91,714,000 after buying an additional 323,518 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in Merus by 90.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 521,339 shares of the biotechnology company's stock worth $30,848,000 after acquiring an additional 247,813 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D acquired a new position in Merus in the third quarter valued at about $1,870,000. Institutional investors own 96.14% of the company's stock.

Merus Price Performance

Shares of Merus stock traded up $0.31 on Thursday, hitting $39.65. 698,675 shares of the company's stock traded hands, compared to its average volume of 808,818. Merus has a one year low of $31.27 and a one year high of $61.61. The stock has a market capitalization of $2.71 billion, a PE ratio of -10.04 and a beta of 1.10. The firm's 50-day moving average price is $44.13 and its two-hundred day moving average price is $49.35.

Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, analysts forecast that Merus will post -3.89 earnings per share for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.